CIK 0000882095
GILD GILEAD SCIENCES, INC.
Insider trading from SEC Form 4. Last filing Nov 27, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
1
with a Form 4 at this company
Signals
Open-market buys and sells at GILEAD SCIENCES, INC., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 30Weak | sell | Bluestone Jeffrey director | $620k | 6,788 | -43% | - |
Congressional trades
16 trades in GILD disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Tommy Tuberville Senate · R-AL | Sale | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 8, 2024 | 819 days after the trade |
| Alan Armstrong Senate · R-OK | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Mar 27, 2026 | 116 days after the trade |
| Jared Moskowitz House · D-FL | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 6, 2026 | 44 days after the trade |
| Jared Moskowitz House · D-FL | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 6, 2026 | 44 days after the trade |
| Josh Gottheimer House · D-NJ | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Jan 27, 2026 | 30 days after the trade |
| Val T. Hoyle House · D-OR | Sale | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Sep 23, 2025 | 17 days after the trade |
| Val T. Hoyle House · D-OR | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Oct 29, 2024 | 318 days after the trade |
| Jefferson Shreve House · R-IN | Sale | GILD Gilead Sciences, Inc. - Common Stock | $15k to $50k | May 12, 2025 | 41 days after the trade |
| Marjorie Taylor Greene House · R-GA | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Jun 6, 2025 | 12 days after the trade |
| Josh Gottheimer House · D-NJ | Sale | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 14, 2025 | 28 days after the trade |
| John Boozman Senate · R-AR | Sale | GILD Gilead Sciences Inc | $1,001 to $15k | Apr 16, 2025 | 28 days after the trade |
| Marjorie Taylor Greene House · R-GA | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 5, 2025 | 1 day after the trade |
| Marjorie Taylor Greene House · R-GA | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | May 5, 2025 | 1 day after the trade |
| Carol D. Miller House · R-WV | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Mar 10, 2025 | 32 days after the trade |
| Jefferson Shreve House · R-IN | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $15k to $50k | Mar 31, 2025 | 11 days after the trade |
| Josh Gottheimer House · D-NJ | Purchase | GILD Gilead Sciences, Inc. - Common Stock | $1,001 to $15k | Mar 7, 2025 | 34 days after the trade |
Transactions
The last 5 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | Bluestone Jeffrey director | MOption exercise Common Stock | +5,879 | $61.17 | $360k | 11,587 | Nov 27, 2024 |
| Nov 26, 2024 | Bluestone Jeffrey director | MOption exercise Common Stock | +4,121 | $61.35 | $253k | 15,708 | Nov 27, 2024 |
| Nov 26, 2024 | Bluestone Jeffrey director | SOpen-market sale Common Stock | -6,788 | $91.39 | $620k | 8,920 | Nov 27, 2024 |
| Nov 26, 2024 | Bluestone Jeffrey director | MOption exercise Non-qualified Stock Option (Right to Buy)derivative | -5,879 | $0.00 | $0 | 0 | Nov 27, 2024 |
| Nov 26, 2024 | Bluestone Jeffrey director | MOption exercise Non-qualified Stock Option (Right to Buy)derivative | -4,121 | $0.00 | $0 | 11,730 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.